Hey Cheri!
Sorry to hear you wound up in the hospital. Definitely a drag.
This Estybon trial at Columbia with Dr. Raza does in fact involve a continuous IV "24-hour infusion administered three times a week every other week" for 23 weeks -- longer if it produces results.
Folks treated with that dosing schedule in the Phase 1 clinical trial had a median survival of 49 weeks. The Phase 1 trial
at Mt. Sinai is still recruiting. There's a
Phase 1 study of oral Estybon at Columbia, as well. It's not clear to me from the description whether it's inpatient.
The NJ trial is definitely closer and may be less stressful than shuttling back and forth to NYC.
Hope the infection/fever gets under control quickly!
Take care,
Greg
__________________
Greg, 59, dx MDS RCMD Int-1 03/10, 8+ & Dup1(q21q31). NIH Campath 11/2010. Non-responder. Tiny telomeres. TERT mutation. Danazol at NIH 12/11. TX independent 7/12. Pancreatitis 4/15. 15% blasts 4/16. DX RAEB-2. Beginning Vidaza to prep for MUD STC. Check out my blog at
www.greghankins.com